Rebalix
UBS · sheet of 10 September 2026
UBS · sheet of 10 September 2026ETF sheet · official issuer and register data
UBS MSCI Switzerland hUSD ETF USD dis
CH0226274212 · CH0226274212 · USD · domicile Switzerland
EquityUSD-hedged share classSFDR art. 6
Index tracked: MSCI Switzerland 100% hedged to USD Total Return Net
- TER
- 0.23%+ trans. 0.11%
- Fund size
- —
- Tracking difference
- +0.02%3-year avg
- 🇮🇹 tax rate
- —white list not published
- Replication
- Physical
- Income
- Distributingmonthly
Launch 31 Oct 2013 · costs from the KID as of 26 Aug 2026 · 3 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 2 Sept 2026
The investment objective of the subfund is to track the price and income performance before costs of the MSCI Switzerland 100% hedged to USD (Net Return). This subfund invests in shares of companies that are included in the MSCI Switzerland 100% hedged to USD (Net Return) and in shares that are not represented in the MSCI Switzerland 100% hedged to USD (Net Return) but which have been announced to be included in the MSCI Switzerland 100% hedged to USD (Net Return) and other investments permitted under the fund contract. In principle, the performance of…
Performance since series start (in euro) — base 100
31 Oct 2013 → 8 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +20.6% |
| 3 years | +39.6% |
| 5 years | +46.8% |
| 10 years | +161.7% |
| Since series start | +256.7% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 11.65% | 12.77% | 13.54% |
| Max drawdown | −11.23% | −17.15% | −22.03% |
| Sharpe | 1.38 | 0.78 | 0.29 |
| Sortino | 2.04 | 1.05 | 0.40 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · CH0226274212 · CH02262742121
RebalixCH0226274212 · CH0226274212 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · fund with dividends reinvested by Rebalix on each ex-date (no issuer total-return series); index from the declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +21.29% | +21.52% | −0.22% |
| 2024 | +10.34% | +10.34% | +0.00% |
| 2023 | +10.02% | +9.74% | +0.28% |
| 2022 | −15.01% | −14.78% | −0.23% |
| 2021 | +24.15% | +24.36% | −0.21% |
Distributions · per share, in USD
Frequency: monthly · last 12 months: 0.2795 USD (0.81% of NAV) · last ex-date 20 Apr 2026
| Year | Payments | Total (USD) | Dividend yield |
|---|---|---|---|
| 2026 | 2 | 0.2795 | — |
| 2025 | 3 | 0.551 | +2.09% |
| 2024 | 1 | 0.4825 | +1.98% |
| 2023 | 1 | 0.443 | +1.97% |
| 2022 | 1 | 0.378 | +1.40% |
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.
Listing venues
ESMA register (FIRDS) and official exchange lists
UFUP · Börse Hamburg, Börse Hannover, Tradegate Exchange
+ 4 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/CH0226274212
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/CH0226274212
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · CH0226274212 · CH02262742122